Jardiance and Metformin Interaction: What Women Need to Know

Import from '@/components/mdx'

Can You Take Jardiance With Metformin?

Yes. Jardiance and metformin are frequently prescribed together, and the combination is supported by an FDA-approved fixed-dose tablet (Synjardy). The two drugs lower blood glucose through entirely different mechanisms, so they complement each other rather than interfere at the pharmacokinetic level. No dose adjustment of either drug is needed simply because they are co-administered, provided your kidneys are working adequately.

The combination is recommended in the 2024 American Diabetes Association Standards of Care for adults with type 2 diabetes who have established cardiovascular disease, chronic kidney disease (CKD), or who need additional HbA1c reduction on metformin alone.

How Each Drug Works

Metformin is a biguanide. It suppresses hepatic glucose production, improves insulin sensitivity in muscle, and modestly reduces intestinal glucose absorption. It does not stimulate insulin secretion, so hypoglycemia is rare when it is used alone.

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It blocks glucose reabsorption in the proximal renal tubule, causing the kidneys to excrete roughly 70 grams of glucose per day in urine. That glucose excretion also drives a mild osmotic diuresis and caloric deficit, which contributes to weight loss of approximately 2 to 3 kg in clinical trials.

Because their targets are completely different (hepatic glucose output vs. Renal glucose reabsorption), there is no competition for enzymes or transporters. Neither drug is metabolized by CYP450 enzymes in a way that affects the other.

The Pharmacodynamic Interaction: Additive Glucose Lowering

The real interaction is pharmacodynamic, not pharmacokinetic. Both drugs lower blood glucose, so together they lower it more than either does alone. In the EMPA-REG OUTCOME trial of 7,020 adults with type 2 diabetes and established cardiovascular disease, approximately 74% of participants were already on metformin when empagliflozin was added. Mean HbA1c fell by 0.54 percentage points more in the empagliflozin group than placebo at 206 weeks.

That additive effect is desirable for glycemic control. It becomes a risk only when a third agent that does stimulate insulin (a sulfonylurea or insulin) is added, which is when hypoglycemia risk rises.

How the Two Drugs Are Cleared Differently (and Why That Matters for Women)

Empagliflozin is primarily cleared by UGT1A3 and UGT2B7-mediated glucuronidation, not by CYP enzymes. Metformin is not metabolized at all. It is excreted unchanged by the kidneys via organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K).

This renal-only clearance is why kidney function governs metformin safety. When eGFR falls, metformin accumulates, and lactate clearance drops, raising the risk of lactic acidosis. The FDA metformin prescribing information now uses eGFR thresholds rather than serum creatinine alone: metformin is contraindicated when eGFR is <30 mL/min/1.73m², and the benefit-risk balance requires reassessment when eGFR is between 30 and 45.

Why Kidney Function Differs Between Women and Men

Women typically have lower muscle mass than men, so serum creatinine systematically underestimates kidney impairment in female patients when older Cockcroft-Gault equations are used. The CKD-EPI 2021 equation, which the National Kidney Foundation now recommends, no longer includes a sex coefficient but performs more equitably across sex and race. Ask your clinician which equation your lab uses to calculate eGFR. A creatinine that looks "normal" for a woman may still correspond to meaningfully reduced GFR.

Empagliflozin itself is contraindicated when eGFR is persistently <20 mL/min/1.73m² for glycemic indications, though it can be continued for cardiovascular and kidney-protective indications down to eGFR 20 in some patients per updated FDA labeling. Practically, if your eGFR is in the 20 to 45 range, your clinician needs to review the dose and indication of each drug individually.

Monitoring Checklist Before Starting the Combination

• Baseline eGFR and serum creatinine
• Urine albumin-to-creatinine ratio (renal health screen)
• HbA1c and fasting glucose
• Blood pressure (both drugs modestly lower it; watch for orthostatic symptoms)
• Pregnancy test if you are of reproductive age

Female-Specific Side Effects and Risk Profile

Genital Mycotic Infections: The Real Conversation Women Deserve

This is the side effect most relevant to women, and it is consistently underemphasized in general diabetes resources. In the EMPA-REG OUTCOME trial, genital mycotic infections occurred in 14.5% of women on empagliflozin 10 mg vs. 2.6% on placebo. That is a more than fivefold higher rate. The glucosuria (sugar in urine) that makes SGLT2 inhibitors work is also a growth medium for Candida albicans.

Practical steps to reduce recurrence:

• Wipe front to back and keep the perineal area dry
• Change out of wet clothing or swimwear promptly
• Discuss topical antifungal prophylaxis with your clinician if you experience two or more infections within three months
• Recurrent vulvovaginal candidiasis warrants evaluation; do not assume it is always empagliflozin-related

Metformin does not increase genital infection risk. If you tolerate metformin without vaginal infections but develop them after adding empagliflozin, the SGLT2 inhibitor is the likely cause.

Urinary Tract Infections

The FDA label for empagliflozin notes an increased risk of urinary tract infections (UTIs). Women already have a baseline UTI incidence three to eight times higher than men, so this deserves explicit counseling. Symptoms of a complicated UTI (fever, back pain, rigors) should prompt immediate evaluation and temporary drug hold, as urosepsis has been reported with SGLT2 inhibitors.

Weight and Metabolic Effects in Women

Women in empagliflozin trials lost slightly less weight on average than men in absolute terms, though proportional body weight reduction was similar. The osmotic diuresis effect also means early weight loss partly reflects fluid, not fat. A pooled analysis of SGLT2 inhibitor trials found women lost approximately 1.8 kg vs. Men's 2.2 kg at 24 weeks, a difference that may relate to sex differences in baseline water-to-fat ratio and estrogen-mediated fluid retention.

Women With PCOS: A Special Case

Polycystic ovary syndrome (PCOS) affects roughly 10% of women of reproductive age and is the most common endocrine disorder in this group. Metformin is one of the most widely prescribed off-label treatments for PCOS, targeting the insulin resistance that drives much of the hormonal dysregulation. Whether empagliflozin adds meaningful benefit for PCOS-related outcomes beyond glycemic control is still under study.

A practical life-stage framework for women with PCOS on this combination:

| Life stage | Metformin role in PCOS | Adding empagliflozin: considerations | |---|---|---| | Reproductive years, not TTC | Improves cycle regularity, insulin resistance | May augment weight loss; strong contraception required | | Trying to conceive (TTC) | May improve ovulation; often continued into 1st trimester | Empagliflozin must be stopped; no safety data in TTC period | | Pregnant | Some clinicians continue through 1st trimester for PCOS; evidence is mixed | Contraindicated; stop before conception if planned | | Postpartum / breastfeeding | Often restarted; passes into breast milk in small amounts | Contraindicated during lactation | | Perimenopause | Insulin resistance worsens; metformin often continued | Empagliflozin's cardiovascular benefit may be increasingly relevant |

The 2023 international PCOS evidence-based guideline does not yet address SGLT2 inhibitor use in PCOS, reflecting the evidence gap. Women with PCOS taking this combination should consider themselves early adopters and discuss this explicitly with their provider.

Pregnancy, Lactation, and Contraception (Required Reading)

Both drugs are contraindicated in the second and third trimesters of pregnancy. This is non-negotiable.

Empagliflozin in Pregnancy

Empagliflozin crosses the placenta. In animal studies, it caused adverse fetal renal development during periods of nephrogenesis (which in humans corresponds to the second and third trimesters). There are no adequate, well-controlled studies in pregnant women. The FDA label states: "Based on animal data showing adverse renal effects, JARDIANCE is not recommended during the second and third trimesters of pregnancy." Given the lack of human safety data and the plausible mechanism of harm, most clinicians advise stopping empagliflozin as soon as pregnancy is confirmed, and ideally before conception when planning a pregnancy.

Metformin in Pregnancy

Metformin does cross the placenta and reaches fetal circulation. Its use in gestational diabetes has been studied extensively. The MiG (Metformin in Gestational Diabetes) trial found similar neonatal outcomes with metformin vs. Insulin, though offspring showed higher rates of adiposity at age 7 to 9 in some follow-up data. The ACOG practice bulletin on gestational diabetes notes metformin as an acceptable alternative to insulin when patients decline injectable therapy, while acknowledging that long-term offspring data are still accumulating.

For PCOS, some endocrinologists continue metformin through the first trimester to reduce miscarriage risk, but this is off-label and debated. The evidence base is mixed and the decision should be individualized.

Lactation

Empagliflozin passes into human breast milk in unknown quantities. Because of potential effects on the developing infant kidney and the fact that young infants cannot tolerate glucosuria, empagliflozin should not be used while breastfeeding. Metformin does pass into breast milk at low concentrations; the relative infant dose is estimated at approximately 0.3 to 0.7% of the weight-adjusted maternal dose, and LactMed classifies it as generally compatible with breastfeeding, though some clinicians prefer to monitor infant blood glucose.

Contraception Requirement

If you are taking empagliflozin and have any possibility of becoming pregnant, reliable contraception is necessary. Because SGLT2 inhibitors carry a renal teratogenicity signal, the same precaution applies here as to other drugs with fetal risk. Discuss your contraception plan openly with your clinician.

Who This Combination Is Right For and Who Should Reconsider

Strong candidates

• Women with type 2 diabetes and established cardiovascular disease needing glycemic plus cardioprotective therapy
• Women with type 2 diabetes and CKD (eGFR 20 to 60 range) where both drugs have guideline-backed kidney-protective roles at appropriate thresholds
• Women with HbA1c above target on metformin monotherapy who cannot tolerate a sulfonylurea or GLP-1 due to cost, GI side effects, or other reasons
• Perimenopausal women with worsening insulin resistance who have existing cardiovascular risk factors

Use with caution or avoid

• eGFR <30 mL/min/1.73m² (metformin contraindicated; empagliflozin glucose-lowering benefit is lost below eGFR 30 and only cardiovascular indications apply)
• Recurrent vulvovaginal candidiasis or urinary tract infections (empagliflozin will worsen this pattern)
• Women planning pregnancy within 3 to 6 months (switch before conception)
• Active or high-risk urinary tract infection at time of starting
• Women on a very low-carbohydrate or fasting regimen without dose adjustment (risk of euglycemic diabetic ketoacidosis, which SGLT2 inhibitors can provoke even at near-normal glucose levels)

Euglycemic Diabetic Ketoacidosis: The Hidden Risk in Women on Low-Carb Diets

Euglycemic diabetic ketoacidosis (euDKA) is a serious complication of SGLT2 inhibitors. Blood glucose is often only mildly elevated (below 250 mg/dL) so the diagnosis is easily missed. It occurs when ketogenesis is accelerated but the usual hyperglycemia signal is absent because the SGLT2 inhibitor is clearing glucose in urine.

Women who follow low-carbohydrate diets for PCOS weight management or who intermittently fast are at elevated risk. A 2020 case series in Diabetes Care documented that surgical stress, prolonged fasting, and low-carb intake each independently triggered euDKA in SGLT2 inhibitor users. Metformin does not independently cause DKA, but the combination context does not reduce the risk from empagliflozin.

Signs to watch for: nausea, vomiting, abdominal pain, shortness of breath, or just feeling "off" while on this combination. Checking urine or blood ketones before concluding it is a stomach bug is worthwhile if you are on an SGLT2 inhibitor.

Lactic Acidosis: Separating Real Risk From Theoretical Concern

Lactic acidosis from metformin is rare but potentially fatal. The reported incidence is approximately 3 cases per 100,000 patient-years, far lower than early warnings suggested. The risk is concentrated in people with renal impairment, liver disease, heart failure with hemodynamic instability, or who consume excessive alcohol.

Adding empagliflozin does not directly increase lactic acidosis risk. Empagliflozin actually reduces the risk of hospitalization for heart failure and worsening renal function in people with diabetes and cardiovascular disease, based on EMPA-REG OUTCOME data, which means it may indirectly improve the conditions that predispose to metformin accumulation. Still, if eGFR declines on follow-up to <45, your clinician should reassess the metformin dose.

Women-specific note: dehydration from SGLT2 inhibitor-driven osmotic diuresis, compounded by nausea, vomiting, or diarrhea from metformin GI side effects, can reduce renal perfusion acutely. The combination during gastroenteritis warrants a temporary hold of both drugs until you are eating and drinking normally. This "sick day rule" applies regardless of baseline kidney function.

Drug Interactions Beyond Metformin: What Else to Watch

While this article focuses on the Jardiance-metformin combination, empagliflozin has several interactions relevant to women across life stages.

Diuretics

Empagliflozin acts as a mild osmotic diuretic. Adding it to a thiazide or loop diuretic increases dehydration and hypotension risk. Perimenopausal women already managing blood pressure with hydrochlorothiazide should have blood pressure monitored within two to four weeks of starting empagliflozin.

Insulin and Sulfonylureas

Neither metformin nor empagliflozin alone causes hypoglycemia, but adding either to insulin or a sulfonylurea increases hypoglycemia risk. The FDA Jardiance label recommends considering a dose reduction of the insulin or sulfonylurea when empagliflozin is added.

Contrast Media and Iodinated Dye Procedures

Metformin should be held 48 hours before and after iodinated contrast procedures when eGFR is <60, per American College of Radiology guidance, because contrast can acutely impair kidney function and precipitate metformin accumulation.

Hormonal Contraceptives

There is no clinically significant pharmacokinetic interaction between empagliflozin or metformin and combined oral contraceptives. Both drugs remain effective. Women who use ethinyl estradiol-containing contraceptives and have poorly controlled diabetes should be aware that high-dose estrogen can itself worsen insulin resistance.

What the Evidence Gap Looks Like for Women

Women made up only about 29% of participants in EMPA-REG OUTCOME. Cardiovascular outcomes data are therefore largely extrapolated from a male-majority trial to women. The EMPEROR-Reduced and EMPEROR-Preserved trials for heart failure included approximately 24% women. Subgroup analyses suggest similar relative risk reductions in women, but the absolute numbers are small and formal interaction tests were not significant.

For PCOS, fertility outcomes, postpartum use, and perimenopausal metabolic disease, essentially no randomized controlled trial data exist. This is not a minor caveat. Prescribing decisions in these contexts rest on physiological reasoning, small observational studies, and clinical judgment rather than the same evidence base that exists for the male-majority cardiovascular trials.

Practical Dosing and Starting the Combination

Standard starting doses when initiating the combination from scratch:

• Metformin: 500 mg twice daily with meals, titrated over four to eight weeks to a maximum of 2,550 mg/day in divided doses to minimize GI side effects
• Empagliflozin: 10 mg once daily in the morning, with or without food; the dose may be increased to 25 mg once daily after four weeks if additional glycemic lowering is needed and eGFR remains adequate

The fixed-dose combination tablet Synjardy is available as empagliflozin 5 mg/metformin 500 mg, empagliflozin 5 mg/metformin 1,000 mg, empagliflozin 12.5 mg/metformin 500 mg, and empagliflozin 12.5 mg/metformin 1,000 mg. Synjardy XR provides the extended-release metformin formulation, which reduces GI side effects and suits once-daily dosing.

Check eGFR again at six to twelve weeks after starting or uptitrating empagliflozin, and annually thereafter. The combination should be held on the morning of any surgical procedure and restarted only after adequate oral intake and stable renal function.